| FDA Approves Ensitrelvir as First Oral Postexposure Prevention Option for COVID-19 |
| Friday, June 05, 2026 01:23 PM |
| The FDA has approved ensitrelvir (Xocova) for postexposure prophylaxis of COVID-19 in adults and children 12 years or older, making it the first and only oral antiviral authorized to help prevent symptomatic infection after exposure. Read more. |